Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure
- 25 September 2003
- journal article
- editorial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 42 (7), 1234-1237
- https://doi.org/10.1016/s0735-1097(03)00948-3
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.European Journal of Heart Failure, 2003
- Multi-chamber pacing: a perfect solution for cardiac mechanical dyssynchrony?European Heart Journal, 2003
- Statins and chronic heart failure: do we need a large-scale outcome trial?Journal of the American College of Cardiology, 2002
- Is aspirin ″the weakest link” in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular diseaseProgress in Cardiovascular Diseases, 2002
- Outcome studies with device therapy in patients with heart failure.Journal of Cardiovascular Electrophysiology, 2002
- For Debate: Preventing atherosclerotic events with aspirinBMJ, 2002
- Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ‐2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001European Journal of Heart Failure, 2001
- The heart failure epidemic: exactly how big is it?Published by Oxford University Press (OUP) ,2001
- Is the prognosis of heart failure improving?European Journal of Heart Failure, 1999
- Does Increased Access to Primary Care Reduce Hospital Readmissions?New England Journal of Medicine, 1996